

Review Article

Genome editing for blood disorders: state of the art and recent advances

Marianna Romito¹, Rajeev Rai¹, Adrian J. Thrasher^{1,2} and  Alessia Cavazza^{1,2}

¹Infection, Immunity and Inflammation Program, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, U.K.; ²NIHR Great Ormond Street Hospital Biomedical Research Centre, London, U.K.

Correspondence: Alessia Cavazza (a.cavazza@ucl.ac.uk)



In recent years, tremendous advances have been made in the use of gene editing to precisely engineer the genome. This technology relies on the activity of a wide range of nuclease platforms — such as zinc-finger nucleases, transcription activator-like effector nucleases, and the CRISPR–Cas system — that can cleave and repair specific DNA regions, providing a unique and flexible tool to study gene function and correct disease-causing mutations. Preclinical studies using gene editing to tackle genetic and infectious diseases have highlighted the therapeutic potential of this technology. This review summarizes the progresses made towards the development of gene editing tools for the treatment of haematological disorders and the hurdles that need to be overcome to achieve clinical success.

Introduction

Genome engineering has endowed the scientific community with the ability to artificially modify genetic information, unlocking the potential of traditional medicine to new therapeutic approaches. Gene editing represents a platform in which programmable DNA nucleases specifically recognize a target genomic sequence where they introduce permanent genetic modifications. Four major classes of targeted nucleases have been described so far: meganucleases, zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the CRISPR/Cas9 system (reviewed in [1]). These nucleases are designed to create double-strand breaks (DSBs) into target DNA sequences, triggering the activation of two major endogenous cellular repair mechanisms: non-homologous end joining (NHEJ) and homologous recombination (HR) [2]. NHEJ is efficient but error-prone, thus repair of the break site results in small DNA insertions or deletions (indels) [3]. Indels can disrupt target genes by shifting the reading frame or introducing stop codons, with consequent production of non-functional proteins. In contrast, HR results in accurate repair through the use of an undamaged DNA template with homology to the sequence flanking the DSB. Each of these pathways — NHEJ or HR — could potentially be exploited for therapeutic purposes. CRISPR/Cas9-based genome editing has been widely used in proof-of-principle preclinical studies holding great promise for further clinical applications. This review will focus on the application of precise editing to treat monogenic disorders affecting the haematopoietic system and on the factors that will determine its success in the clinical setting.

Therapeutic genome editing

For many haematological conditions, such as primary immunodeficiencies and haemoglobinopathies, the only curative treatment is histocompatibility leukocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplantation (HSCT), which replaces defective haematopoietic lineages with functional cells. The limitations of this procedure include donor availability with the consequent risk of graft rejection, incomplete immune reconstitution, graft-versus-host disease, death and/or long-term dysfunction arising from the conditioning regimen [4,5]. Transplantation of autologous, genetically modified stem cells could represent an alternative to allogeneic HSCT, and many groups have worked over the

Received: 21 January 2019
Revised: 4 March 2019
Accepted: 8 March 2019

Version of Record published:
9 April 2019

last few decades toward achieving efficient and safe gene transfer to haematopoietic stem cells (HSCs). In order for gene therapy to be a viable and potentially life-long treatment, it is necessary to (1) correct a sufficient amount of long-term repopulating HSCs, (2) achieve a stable and regulated expression of the therapeutic gene, and (3) ensure that the process is safe. Pioneering gene therapy approaches for severe combined immunodeficiency disorders (SCID) using retroviral vectors have demonstrated the applicability of the technology to treat rare genetic diseases affecting the haematopoietic system [6]. However, viral vectors carry a potential risk of genotoxicity due to their semi-random integration pattern and to unregulated transgene expression in target cells [7,8]. Using autologous genetically modified haematopoietic stem and progenitor cells (HSPCs), gene editing could represent an alternative to conventional gene therapy and overcome some of its limitations. Engineered endonucleases that introduce DSBs at specific sequences in the genome offer much more control over viral vector site integration; moreover, the site-specific insertion of DNA or correction of a disease-causing mutation *in situ* guarantees that physiologically regulated gene expression is preserved. There are different gene editing applications based on the two main repair mechanisms utilized by the target cells to correct the DSB. HDR (homology-directed repair) can be used to either insert a gene into a specific ‘safe harbour’, into its own locus or to specifically repair small or point mutations in the defective gene. In contrast, if NHEJ takes place, the generated indels could abolish the expression of the protein, or the function of a regulatory region, and thus this repair pathway can be utilized to treat those diseases for which mutating a genetic element may result in clinical benefit [9].

HDR-mediated genome editing

Site-specific gene correction

Site-specific correction of disease-causing mutations represents the most straightforward approach to repair a faulty gene responsible for a monogenic disorder. *In situ* correction has the advantage of preserving endogenous regulatory regions and physiological gene expression, which would be particularly advantageous when targeting tightly regulated genes. Conditions for which a single or predominant mutation underlies the disease would seem to be the most amenable to this approach (Figure 1). An example is sickle cell disease (SCD). SCD is an autosomal recessive disorder affecting millions of people worldwide and is caused by an A-to-T point mutation in the sixth codon of the β -globin gene (HBB), resulting in the production of a defective globin that confers a hook/sickle shape to red blood cells [10]. ZFNs and CRISPR/Cas9 together with a donor template delivered via integration-defective lentiviral vectors (IDLV) or single-stranded DNA oligonucleotides (ssODN) have been extensively used to correct the SCD-causing mutation in different cell types [11–14]. In clinically relevant cells such as HSPCs, ZFN-mediated correction of the SCD mutation was achieved in up to 40% of the cells [15–17]. However, the frequency of correction dropped when cells were transplanted into immunodeficient mice, with only ~0.2–2.3% of engrafted long-term repopulating HSPCs harbouring a corrected copy of the HBB gene at more than 12 weeks after transplantation, thus achieving rates of editing far below the level of therapeutic relevance. To overcome this limitation, Dever et al. deployed a strategy that allows the enrichment of edited HSPCs, by including a selectable marker into the HDR donor cassette delivered via a serotype 6 adeno-associated viral vectors (AAV6). Using this approach, the authors showed that >97% of cells engrafted into immunodeficient mice were gene targeted, a significant increase compared with mice transplanted with unselected gene-edited HSPCs (~3%). Despite the increase in HDR rate, selection of targeted HSPCs before transplantation yielded an overall lower engraftment rate and recovery of fewer cells compared with standard protocols, indicating that further improvements in the selection technique and cell culture conditions are required before translating this strategy into the clinics.

Site-specific genome editing has also been attempted by the group of Harry Malech for the treatment of chronic granulomatous disease (CGD). CGD is a life-threatening disease caused by mutations in any of the five subunits (gp91^{phox}, p22^{phox}, p40, p47^{phox}, p67^{phox}) that comprise the phagocyte nicotinamide adenine dinucleotide phosphate oxidase (NADPH) complex. Apart from gp91^{phox}, which is encoded by the CYBB gene located on the X chromosome, the remaining mutated subunits lead to an autosomal recessive form of the disease. While mutations are scattered across the genes for all other CGD patient phox genes, >80% of p47^{phox}-CGD patients are homozygous for a two-nucleotide deletion in exon 2 of the NCF1 gene, resulting in a codon frameshift and abrogation of p47^{phox} expression [18]. Interestingly, the same mutation is found in the NCF1 pseudogenes NCF1B and NCF1C. By delivering ZFNs and an AAV6 containing a correct exon 2 sequence as a template for HDR, Merling et al. replaced the mutated exon in the NCF1 locus as well as in its pseudogenes, restoring oxidase function in 6% of myeloid cells differentiated from patient’s derived p47-CGD HSPCs and showing, for the first time, that rescue of a pseudogene function can correct a monogenic disorder




Figure 1. HDR-mediated genome editing.

HDR is a cellular pathway that can be exploited to modify genomic sequences via site-specific gene correction of mutations (green box) or insertion of a correct gene (orange box). Mutations in the β -globin locus cause SCD and/or β -thalassaemia. Abnormal β -globin (β_s phenotype) is caused by an A-to-T point mutation; therefore, site-specific correction of the mutation could revert the disease phenotype. The same holds true for some forms of CGD, where the presence of mutation hotspots in the *CYBB* and *NCF1A* genes make this disease amenable to site-specific correction through gene editing. β -globin loss (β_0 phenotype) in β -thalassaemia or absence of the common gamma chain of IL-2 receptor in SCID-X1 is caused by mutations scattered around the respective genes. Healthy phenotypes in β -thalassaemia (red box) or SCID-X1 (orange box) patients can be reconstituted via insertion of a correct gene in its own endogenous locus or in a 'safe harbour' genomic region.

[19]. In parallel, De Ravin et al. developed a CRISPR–Cas9 system to repair a point mutation in the *CYBB* gene, which is responsible for 6% of the cases of X-linked CGD (X-CGD), using a ssODN as a template to promote HDR-mediated gene repair. Seamless repair of the missense mutation restored $gp91^{phox}$ protein expression and function in X-CGD HSPC-derived myeloid cells, and the amount of corrected cells decreased by <50% after transplant into immunodeficient mice [20].

Site-specific gene insertion

One potential issue with site-specific gene correction is that the majority of genetic diseases are caused by mutations spanning across the genes, thus requiring tailoring of gene editing reagents for each individual patient. A more universal and attractive strategy would be to target an entire gene cassette to the desired locus so that, once integrated, the transgene would functionally correct all disease-causing mutations. To this aim, a whole expression cassette, including regulatory elements, can be inserted into a 'safe harbour', defined as a genomic region that is able to accommodate the expression of newly integrated DNA without adverse effects on the host cell or organism

[21], such as the adeno-associated virus integration site 1 (AAVS1) locus. Once a set of safe harbour site-specific nucleases has been designed, the same toolbox could be potentially used to treat many different genetic disorders. Alternatively, it is possible to knock in the functional transgene into its own locus, allowing expression of the gene through its own endogenous regulatory elements. Although this strategy is specific for each single gene/disease, it could be particularly amenable for conditions in which endogenous gene regulation is essential (Figure 1).

Pioneering work by Urnov et al. showed that it is possible to correct a mutation responsible for the X-linked severe combined immune deficiency (SCID-X1) in primary cells using ZFNs directed against the IL-2 receptor common gamma-chain gene (IL2RG). By designing a donor template DNA carrying an exon 5 fragment of IL2RG, the authors reported up to 5% of HDR-mediated editing in primary T cells, paving the way for potential gene correction applications, aimed to treat SCID-X1 [22]. However, the modest rates of editing achieved in primary cells highlighted the limitation of plasmid transfection to deliver the nucleases and the HDR template, in particular when applied to cells sensitive to genetic manipulations such as HSPCs. Lombardi and colleagues first addressed this issue and managed to successfully insert a donor cassette downstream of the IL2RG promoter or in the safe harbour CCR5 locus, using an IDLV to deliver ZFNs and the HDR template to lymphoblastoid primary cells, embryonic stem cells and HSPCs. While this represented an improvement of the editing protocol for primary cells, knock-in rates, especially in therapeutically relevant HSPCs, were extremely low [23]. To overcome the poor integration level observed in repopulating stem cells, the same group then optimized various culture conditions, timing and delivery route of the reagents to enhance the insertion of an IL2RG cDNA cassette into the AAVS1 or the *IL2RG* locus in HSPCs derived from healthy or SCID-X1 donors, achieving up to 11% of gene targeting [24]. More recently, two preclinical studies have shown significant advancement in the correction of the IL2RG locus, by knocking in a full-length *IL2RG* cDNA delivered by an AAV6 donor vector using either the ZFN or CRISPR/Cas9 system [25,26]. Both groups were able to reach therapeutic levels of IL2RG expression in wild-type and SCID-X1 HSPCs, as well as in the more primitive population of HSCs, with *in vitro* and *in vivo* rescue of multi-lineage developmental potential from corrected cells. SCID-X1 represents an ideal target for proof-of-concept gene editing studies, as the tremendous selective advantage that functionally corrected cells have over mutated ones in a SCID setting [27] can compensate for the relatively low rate of HDR-mediated correction in HSPCs. Additional protocol optimization may be required to increase the percentage of gene correction in long-term repopulating stem cells to revert the disease phenotype in blood disorders where such a strong selective advantage is missing.

NHEJ-mediated genome editing

Although gene correction might seem the most immediate approach to therapeutic genome editing, the first clinical trial using targeted nucleases in human patients has relied on NHEJ-based genetic disruption. One advantage of this strategy is that NHEJ tends to be a more active repair pathway compared with HDR, particularly in quiescent stem cells [28]. Another benefit of NHEJ over HDR is that it relies solely on targeting nucleases with no need for designing and producing a donor template, thus making the whole process less laborious and more efficient for a potential clinical application. The first-in-human genome editing trial (NCT01044654) used ZFNs in autologous T cells to target the HIV co-receptor CCR5 [29], with the aim to mimic naturally occurring mutations that abolish its expression and engender resistance to HIV infection [30]. The clinical outcome indicated that this NHEJ-based approach was safe for patients and able to confer a survival advantage *in vivo* against HIV. Preclinical *in vitro* and *in vivo* studies demonstrated the feasibility and safety of ZFN-based CCR5 disruption also in HSPCs, providing a potentially life-long treatment to HIV-infected patients [31]. The technology is currently being evaluated in an ongoing clinical trial (NCT02500849) as a collaboration between City of Hope Medical Center and Sangamo Therapeutics.

The indels generated by NHEJ repair may be useful for disrupting not only coding sequences but also non-coding regulatory elements. For example, mutation of the erythroid-specific enhancer of *BCL11A* has been shown to increase fetal haemoglobin (HbF) expression and treat haemoglobinopathies. From the observations of new-born babies with β -globin defects [32], it is clear that by maintaining HbF expression it is possible to reduce or totally abolish the symptoms related to SCD or β -thalassemia [33–35]. *BCL11A* plays a crucial role in HbF transcriptional repression [36,37], in accordance with the rescue of therapeutically relevant levels of HbF expression in *BCL11A* knock-out murine models [38,39]. By using different gene editing platforms, many groups have shown that knock-out of *BCL11A* erythroid-specific enhancer restores high HbF levels, without compromising cell viability or function [38,40,41] (Figure 2). Preclinical studies made by Sangamo Therapeutics using ZFNs to target this region have demonstrated the therapeutic and clinical potential of the




Figure 2. NHEJ-mediated genome editing.

Genome editing can re-equilibrate the lost balance in the haemoglobin structure caused by the presence of defective subunits (pink and yellow boxes). The excess of one kind of haemoglobin chain — either α - or β -globin — can be reduced via NHEJ gene disruption (green box). Potential target sites to restore β -globin expression using an NHEJ-based approach are fetal haemoglobin (HbF) silencers (2, purple box), genomic regions regulating the expression of these silencers (1, purple box) or sites that can reproduce the HPFH phenotype (3, purple box).

approach, obtaining engraftment of modified long-term HSCs *in vivo* and persisting production of high levels of HbF in animals [42–44]. At the beginning of the year, a Phase 1/2 clinical trial has started to evaluate the safety of their product in six β -thalassaemia patients (NCT03432364); in parallel, CRISPR Therapeutics and Vertex Pharmaceuticals have opened a Phase 1/2 clinical trial on twelve SCD-affected subjects to test the safety of their CRISPR–Cas9 platform targeting the BCL11A enhancer in HSPCs (NCT03745287).

Apart from BCL11A, several other modulators of HBB expression have been identified as potential targets of NHEJ-based gene disruption approaches (Figure 2). In particular, it has been shown that CRISPR/Cas9-mediated knock-out of the lymphoma/leukemia-related factor (LRF), an HbF silencer [45], can increase more than five times the level of HbF expression. However, the involvement of LRF in other haematopoietic functions may impair the translation of this approach into the clinic and therefore it requires further investigation [46]. The presence of high levels of HbF in patients affected by the hereditary persistence of fetal haemoglobin (HPFH) benign condition has led several research groups to focus on genome editing strategies that could reproduce large deletions in the β -globin gene cluster and mutations in the γ -globin promoter region [47–49]. It has been shown that the disruption of HGB1 and HGB2 (γ -globin) gene promoter region inhibits the repression of HbF mediated by BCL11A or LRF reversing the globin switching [50,51]. Furthermore, natural HPFH-associated deletions and point mutations have been precisely generated *in vitro* in HSPCs through a CRISPR/Cas9 multiplex strategy [52,53], or a microhomology-mediated end joining microdeletion approach [54]. However, the reactivation of HbF expression at clinically beneficial levels has not been achieved so far, leaving open questions regarding the efficacy [55] and potential side effects *in vivo* [55] of the γ -globin silencer as a therapeutic target for gene editing.

Epigenome and base editing

The great versatility and flexibility of the CRISPR/Cas9 platform and the ability of Cas9 to bind DNA independently from its nuclease activity led to the development of novel tools that could overcome some of the limitations of current gene editing approaches. Indeed, a ‘dead’ catalytically inactive Cas9 endonuclease (dCas9)

has been engineered to tether different enzymatic activities to specific DNA sequences for a variety of applications, including transcriptional regulation and epigenetic modification.

Epigenetic marks and effectors have a crucial impact on chromatin organization and gene expression over time. For example, the effects of these modifications are clearly visible in the γ -to- β haemoglobin switching. Epigenome manipulation of the β -globin gene cluster, such as artificially driven changes that block epigenetic HbF gene silencing, offers a challenging alternative to the permanent alteration of the coding sequence that is achieved with ‘traditional’ genome engineering. Epigenome modifiers, composed of the LSD1 histone demethylase and ZFN [56,57] or TAL effector domains [58], were developed to target the globin locus control region (LCR), force the β -globin looping and restore HbF expression. One of these studies has shown that using this approach it is possible to induce a ~2.5-fold increment in γ -globin expression in different donors [57]. Because LSD1 is essential for erythroid differentiation [59], the long-range precise control of the chromatin structure offers a potentially safer option for therapeutic purposes compared with the LSD1 knock-down or knock-out approach. Other potential epigenetic targets of interest for haemoglobinopathies are represented by the genes involved in the β -globin looping interactions such as methyl cytosine-binding domain proteins and the Mi2 β chromatin remodelling ATPase [60,61], whose manipulation could be used to increase γ -globin gene expression without impairing erythroid differentiation.

As discussed above, the efficiency of HDR is very low due to the higher amount of DSBs being preferentially repaired by NHEJ. To introduce point mutations without using HDR, different platforms based on dCas9 fused to DNA deaminases have been developed for base editing technologies. Since 2016, four generations of base editors (BEs) have been developed from apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBECs) or activation-induced cytidine deaminases combined with either the CRISPR–Cas9 or the CRISPR–Cpf1 system (reviewed in [62]). BEs could be therapeutically relevant to correct disease-causing point mutations or to induce site-specific mutations to disrupt genomic sequences. Although still in their early stage, few reports have shown the applicability of such technologies to treat haemoglobinopathies. Liu et al. [63] showed that plasmid delivery of an adenine BE was able to install a mutation known to confer HPFH and enable HbF production in HEK293T cells. Other two studies reported correction of a mutant HBB allele in β -thalassaemia patient-derived erythroid precursors [64] and primary fibroblasts [65]. Despite being promising tools, BEs activity and editing efficiency in primary cells must be improved before moving from bench to clinic.

Challenges of therapeutic genome editing

Site-specific genome editing has transformed the research field of biology and medicine. Not only can this technique allow the functional study of a particular gene, but it is also amenable to correction of a disease-associated mutation. Despite this exciting prospect, there remain major barriers associated with the editing-based therapeutic treatment of blood disorders that must be addressed to advance clinical applications that rely on genome editing. Some of these challenges include (1) the delivery of the editing machinery *ex vivo* and *in vivo*, (2) the ability to preserve the stemness and achieve high levels of engraftment of HSCs *in vivo*, (3) the identification and reduction in genome-wide off-target effects induced by the nucleases.

The main objective when delivering gene editing reagents is to promote a hit-and-run activity of the nucleases, to allow for the generation of DSBs in a short period of time, while limiting toxicity and off-target activity. For HDR-based gene addition approaches, it is also necessary to deliver the DNA donor template in a transient way, to avoid unwanted integration into non-specific regions of the genome. For decades, various delivery methods, such as electroporation, nanoparticles and viral vectors, have been used to introduce the editing reagents into cells for *ex vivo* or *in vivo* approaches. For *ex vivo* applications, transfection of plasmid DNA is nowadays the least used technique to target primary cells, as reports indicate induction of high toxicity, off-target insertion and host immune response [66,67]. These unwanted effects are observed minimally when delivering nucleases as mRNA or, in the case of Cas9 and the gRNA, in the form of a ribonucleoprotein complex [16,68–70]. Unlike electroporation, viral vectors, such as recombinant AAV and IDLV, have been applied in both *ex vivo* and *in vivo* preclinical studies. In addition to the delivery of editing reagents, their non-integrative properties allow them to be used to provide the donor template for HDR-based gene correction. The relatively low toxicity and non-integrative nature of AAV, together with its ability to achieve high recombination frequencies with small homology regions, have made them desirable genetic tools for efficient human HSPC gene editing [25,71–73]. Despite being safe, one of the drawbacks of AAV is their limited cargo capacity of 4.5 kb that restricts the expression of large transgenes, although it has been recently reported the integration of a cassette with up to 6.5 kb in size using a multiplexing strategy [74]. Delivery through lipid- and gold-based nanoparticles is considered safer *in vivo* compared with the use of viral vectors, but the targeting efficiency is still below therapeutic levels [75,76].

As outlined at the beginning of this review, long-term repopulating HSCs are the ideal target for gene editing of various types of inherited haematological conditions [16]. The therapeutic benefit of gene-corrected HSCs depends on their capacity to engraft and provide long-term production of healthy blood lineage progenitors while maintaining renewable stem cells in transplanted patients. One of the hurdles associated with HSC editing is the low rate of HDR than can be achieved, mainly due to the fact that NHEJ is preferentially utilized to correct DSBs in non-dividing cells. To overcome this problem, various groups have tried either pharmacological or genetic inhibition of NHEJ [77–80], strategies to increase the rates of HDR [81,82] and synchronization of the cell cycle [83], as well as optimization of delivery conditions to enhance knock-in efficiencies. Moreover, strategies to *in vitro* expand primitive HSC while preserving their stem cell qualities have been put in place, with the final aim to advance efforts at HSC modification, engraftment and long-term repopulation in *in vivo* xenotransplantation models [24,72,84].

The intrinsic specificity of the editing machinery permits researchers to modify their chosen gene of interest at a particular locus; however, unintended off-target cleavage at different genomic sites might occur. Being a permanent genetic modification, off-target cleavage could introduce unwanted mutations which may ultimately lead to cancer, posing a huge risk for clinical therapeutic applications involving engineered nucleases. Therefore, evaluation of off-target mutagenesis is an important preclinical criterion that must be taken into account before starting clinical studies. Several off-target detection methods have been developed to assess the safety of gene editing reagents. Early developed approaches have used computational predictions to identify a limited set of genomic regions that show homology with the target site, which can be then examined for a-specific cleavage by deep sequencing [85]. More recently, unbiased methods have been proposed that allow for genome-wide assessment of off-target mutagenesis, and in certain cases can also identify gross chromosomal rearrangements [86–89]. However, these methods do not always reliably pinpoint all potential off-targets and often show a limited sensitivity. To complicate the scenario, one must take into account the baseline level of mutagenesis that exists in normal somatic tissues or that can be caused by cell expansion during the manufacturing process. Dosage and expression pattern of the nucleases, as well as cell number, cell type and features of the genomic target site, may also affect editing specificity. It is difficult to predict the impact that modifications at different genomic sites may have on cell fitness, considering that most likely the vast majority of off-target edits would be functionally neutral. Interpreting the effects of genomic perturbations is challenging and requires the identification and development of functional readouts of safety that must be tailored to the therapeutic cell type of interest. There have been several efforts to increase the specificity of genome-editing systems, such as the development of shorter gRNAs [85], nickase mutants of Cas9, Cas9–FokI fusion protein [90,91], and high-fidelity Cas9 variants [69,92]. The continued improvements of the efficiency and safety of these reagents will be essential to ensure the success of gene editing applications to treat genetic haematological disorders.

Conclusion

During the last few years, gene editing has emerged as a powerful tool for genomic functional studies and therapeutic correction of monogenic disease. Gene editing platforms, such as CRISPR/Cas9 and TALEN, have shown great promise in proof-of-principle preclinical studies to treat haematological disorders, and clinical trials using these tools are now underway. Nonetheless, there remain important challenges that need to be addressed, such as the efficiency and specificity of the editing system, especially when considering targeting of primary stem cells.

Summary

- Genome editing is a rapidly evolving technology that has particular relevance for the treatment of haematological disorders and infectious diseases.
- Blood disorders can be tackled by taking advantage of two main endogenous cell repair mechanisms — NHEJ and HDR — which lead to either disruption of genes and regulatory elements or insertion of a correct gene in a site-specific fashion.
- Despite the tremendous progress, several issues need to be addressed to make genome editing a safer and more effective therapeutic tool.

Abbreviations

AAVS1, adeno-associated virus integration site 1; BEs, base editors; CGD, chronic granulomatous disease; DSBs, double-strand breaks; HDR, homology-directed repair; HPFH, hereditary persistence of fetal haemoglobin; HR, homologous recombination; HSCs, haematopoietic stem cells; HSCT, haematopoietic stem cell transplantation; HSPCs, haematopoietic stem and progenitor cell; IDLV, integration-defective lentiviral vectors; IL2RG, IL-2 receptor common gamma-chain gene; LCR, locus control region; LRF, lymphoma/leukemia-related factor; NHEJ, non-homologous end joining; SCD, sickle cell disease; SCID, severe combined immunodeficiency disorders; SCID-X1, X-linked severe combined immune deficiency; ssODN, single-stranded DNA oligonucleotides; TALENs, transcription activator-like effector nucleases; X-CGD, X-linked CGD; ZFNs, zinc-finger nucleases.

Author Contribution

M.R., R.R. and A.C. wrote the manuscript. M.R. prepared the figures under the supervision of A.C.

Funding

This work was supported by grants from the Wellcome Trust, Great Ormond Street Hospital Children's Charity and by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London.

Acknowledgements

The authors thank Dr Giorgia Santilli and Dr Sara Benedetti for their helpful comments.

Competing Interests

The Authors declare that there are no competing interests associated with the manuscript.

References

- Kim, H. and Kim, J.-S. (2014) A guide to genome engineering with programmable nucleases. *Nat. Rev. Genet.* **15**, 321–334 <https://doi.org/10.1038/nrg3686>
- Liang, L., Deng, L., Chen, Y., Li, G.C., Shao, C. and Tischfield, J.A. (2005) Modulation of DNA end joining by nuclear proteins. *J. Biol. Chem.* **280**, 31442–31449 <https://doi.org/10.1074/jbc.M503776200>
- Lieber, M.R., Ma, Y., Pannicke, U. and Schwarz, K. (2003) Mechanism and regulation of human non-homologous DNA end-joining. *Nat. Rev. Mol. Cell Biol.* **4**, 712–720 <https://doi.org/10.1038/nrm1202>
- Locatelli, F., Kabbara, N., Ruggeri, A., Ghavamzadeh, A., Roberts, I., Li, C.K. et al. (2013) Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. *Blood* **122**, 1072–1078 <https://doi.org/10.1182/blood-2013-03-489112>
- Pai, S.-Y., Logan, B.R., Griffith, L.M., Buckley, R.H., Parrott, R.E., Dvorak, C.C. et al. (2014) Transplantation outcomes for severe combined immunodeficiency, 2000–2009. *N. Engl. J. Med.* **371**, 434–446 <https://doi.org/10.1056/NEJMoa1401177>
- Thrasher, A.J. and Williams, D.A. (2017) Evolving gene therapy in primary immunodeficiency. *Mol. Ther.* **25**, 1132–1141 <https://doi.org/10.1016/j.ymthe.2017.03.018>
- Biasco, L., Rothe, M., Büning, H. and Schambach, A. (2017) Analyzing the genotoxicity of retroviral vectors in hematopoietic cell gene therapy. *Mol. Ther. Methods Clin. Dev.* **8**, 21–30 <https://doi.org/10.1016/j.omtm.2017.10.002>
- David, R.M. and Doherty, A.T. (2017) Viral vectors: the road to reducing genotoxicity. *Toxicol. Sci.* **155**, 315–325 <https://doi.org/10.1093/toxsci/kfw220>
- Porteus, M.H. (2015) Towards a new era in medicine: therapeutic genome editing. *Genome Biol.* **16**, 286 <https://doi.org/10.1186/s13059-015-0859-y>
- Ingram, V. (1959) Abnormal human haemoglobins. III. The chemical difference between normal and sickle cell haemoglobins. *Biochim. Biophys. Acta* **36**, 402–411 [https://doi.org/10.1016/0006-3002\(59\)90183-0](https://doi.org/10.1016/0006-3002(59)90183-0)
- Chang, J.C., Ye, L. and Kan, Y.W. (2006) Correction of the sickle cell mutation in embryonic stem cells. *Proc. Natl Acad. Sci. U.S.A.* **103**, 1036–1040 <https://doi.org/10.1073/pnas.0510177103>
- Zou, J., Mali, P., Huang, X., Dowey, S.N. and Cheng, L. (2011) Site-specific gene correction of a point mutation in human iPSCs derived from an adult patient with sickle cell disease. *Blood* **118**, 4599–4608 <https://doi.org/10.1182/blood-2011-02-335554>
- Sun, N. and Zhao, H. (2014) Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. *Biotechnol. Bioeng.* **111**, 1048–1053 <https://doi.org/10.1002/bit.25018>
- Xie, F., Ye, L., Chang, J.C., Beyer, A.I., Wang, J., Muench, M.O. et al. (2014) Seamless gene correction of β -thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. *Genome Res.* **24**, 1526–1533 <https://doi.org/10.1101/gr.173427.114>
- Hoban, M.D., Cost, G.J., Mendel, M.C., Romero, Z., Kaufman, M.L., Joglekar, A.V. et al. (2015) Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. *Blood* **125**, 2597–2604 <https://doi.org/10.1182/blood-2014-12-615948>
- Hoban, M.D., Orkin, S.H. and Bauer, D.E. (2016) Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. *Blood* **127**, 839–848 <https://doi.org/10.1182/blood-2015-09-618587>
- DeWitt, M.A., Magis, W., Bray, N.L., Wang, T., Berman, J.R., Urbinati, F. et al. (2016) Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. *Sci. Transl. Med.* **8**, 360ra134 <https://doi.org/10.1126/scitranslmed.aaf9336>

- 18 Casimir, C.M., Bu-Ghanim, H.N., Rodaway, A.R., Bentley, D.L., Rowe, P. and Segal, A.W. (1991) Autosomal recessive chronic granulomatous disease caused by deletion at a dinucleotide repeat. *Proc. Natl Acad. Sci. U.S.A.* **88**, 2753–2757 <https://doi.org/10.1073/pnas.88.7.2753>
- 19 Merling, R.K., Kuhns, D.B., Sweeney, C.L., Wu, X., Burkett, S., Chu, J. et al. (2017) Gene-edited pseudogene resurrection corrects p47^{phox}-deficient chronic granulomatous disease. *Blood Adv.* **1**, 270–278 <https://doi.org/10.1182/bloodadvances.2016001214>
- 20 De Ravin, S.S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S. et al. (2017) CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. *Sci. Transl. Med.* **9**, eaah3480 <https://doi.org/10.1126/scitranslmed.aah3480>
- 21 Sadelain, M., Papapetrou, E.P. and Bushman, F.D. (2011) Safe harbours for the integration of new DNA in the human genome. *Nat. Rev. Cancer* **12**, 51–58 <https://doi.org/10.1038/nrc3179>
- 22 Urnov, F.D., Miller, J.C., Lee, Y.-L., Beausejour, C.M., Rock, J.M., Augustus, S. et al. (2005) Highly efficient endogenous human gene correction using designed zinc-finger nucleases. *Nature* **435**, 646–651 <https://doi.org/10.1038/nature03556>
- 23 Lombardo, A., Genovese, P., Beausejour, C.M., Colleoni, S., Lee, Y.-L., Kim, K.A. et al. (2007) Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. *Nat. Biotechnol.* **25**, 1298–1306 <https://doi.org/10.1038/nbt1353>
- 24 Genovese, P., Schirolli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A. et al. (2014) Targeted genome editing in human repopulating haematopoietic stem cells. *Nature* **510**, 235–240 <https://doi.org/10.1038/nature13420>
- 25 Schirolli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L. et al. (2017) Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. *Sci. Transl. Med.* **9**, eaan0820 <https://doi.org/10.1126/scitranslmed.aan0820>
- 26 Pavel-Dinu, M., Wiebking, V., Dejene, B.T., Srifa, W., Mantri, S., Nicolas, C. et al. (2018) Gene correction for SCID-X1 in long-term hematopoietic stem cells. *bioRxiv* [cited 2019 Jan 16]. <https://doi.org/10.1101/397463>
- 27 Bouso, P., Wahn, V., Douagi, I., Horneff, G., Pannetier, C., Deist, F.L. et al. (2000) Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. *Proc. Natl Acad. Sci. U.S.A.* **97**, 274–278 <https://doi.org/10.1073/pnas.97.1.274>
- 28 Mohrin, M., Bourke, E., Alexander, D., Warr, M.R., Barry-Holson, K., Le Beau, M.M. et al. (2010) Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. *Cell Stem Cell.* **7**, 174–185 <https://doi.org/10.1016/j.stem.2010.06.014>
- 29 Tebas, P., Stein, D., Tang, W.W., Frank, I., Wang, S.Q., Lee, G. et al. (2014) Gene editing of *CCR5* in autologous CD4T cells of persons infected with HIV. *N. Engl. J. Med.* **370**, 901–910 <https://doi.org/10.1056/NEJMoa1300662>
- 30 Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müssig, A., Allers, K. et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. *N. Engl. J. Med.* **360**, 692–698 <https://doi.org/10.1056/NEJMoa0802905>
- 31 DiGiusto, D.L., Cannon, P.M., Holmes, M.C., Li, L., Rao, A., Wang, J. et al. (2016) Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. *Mol. Ther. Methods Clin. Dev.* **3**, 16067 <https://doi.org/10.1038/mtm.2016.67>
- 32 Watson, J. (1948) The significance of the paucity of sickle cells in newborn Negro infants. *Am. J. Med. Sci.* **215**, 419–423 <https://doi.org/10.1097/00000441-194804000-00008>
- 33 Huisman, T.H. (1979) Sickle cell anemia as a syndrome: a review of diagnostic features. *Am. J. Hematol.* **6**, 173–184 <https://doi.org/10.1002/ajh.2830060210>
- 34 Perrine, R.P., Brown, M.J., Clegg, J.B., Weatherall, D.J. and May, A. (1972) Benign sickle-cell anaemia. *Lancet* **300**, 1163–1167 [https://doi.org/10.1016/S0140-6736\(72\)92592-5](https://doi.org/10.1016/S0140-6736(72)92592-5)
- 35 Serjeant, G.R. (2013) The natural history of sickle cell disease. *Cold Spring Harb. Perspect. Med.* **3**, a011783 <https://doi.org/10.1101/cshperspect.a011783>
- 36 Menzel, S., Garner, C., Gut, I., Matsuda, F., Yamaguchi, M., Heath, S. et al. (2007) A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. *Nat. Genet.* **39**, 1197–1199 <https://doi.org/10.1038/ng2108>
- 37 Uda, M., Galanello, R., Sanna, S., Lettre, G., Sankaran, V.G., Chen, W. et al. (2008) Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β -thalassaemia. *Proc. Natl Acad. Sci. U.S.A.* **105**, 1620–1625 <https://doi.org/10.1073/pnas.0711566105>
- 38 Bauer, D.E., Kamran, S.C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C. et al. (2013) An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. *Science* **342**, 253–257 <https://doi.org/10.1126/science.1242088>
- 39 Smith, E.C., Luc, S., Croney, D.M., Woodworth, M.B., Greig, L.C., Fujiwara, Y. et al. (2016) Strict in vivo specificity of the Bcl11a erythroid enhancer. *Blood* **128**, 2338–2342 <https://doi.org/10.1182/blood-2016-08-736249>
- 40 Canver, M.C., Smith, E.C., Sher, F., Pinello, L., Sanjana, N.E., Shalem, O. et al. (2015) BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. *Nature* **527**, 192–197 <https://doi.org/10.1038/nature15521>
- 41 Vierstra, J., Reik, A., Chang, K.-H., Stehling-Sun, S., Zhou, Y.-Y., Hinkley, S.J. et al. (2015) Functional footprinting of regulatory DNA. *Nat. Methods* **12**, 927–930 <https://doi.org/10.1038/nmeth.3554>
- 42 Chang, K.-H., Smith, S.E., Sullivan, T., Chen, K., Zhou, Q., West, J.A. et al. (2017) Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34⁺ hematopoietic stem and progenitor cells. *Mol. Ther. Methods Clin. Dev.* **4**, 137–148 <https://doi.org/10.1016/j.omtm.2016.12.009>
- 43 Ando, D., Walters, M.C., Chang, K.-H., Reik, A., Urnov, F.D., Lee, G. et al. (2015) Preclinical studies for the first hematopoietic stem cell (HSC) gene editing trial: phase 1 study of β -thalassaemia with autologous transplantation of zinc finger nuclease-treated HSC to upregulate fetal hemoglobin. *Mol. Ther.* **23**, S93–S94 [https://doi.org/10.1016/S1525-0016\(16\)33844-8](https://doi.org/10.1016/S1525-0016(16)33844-8)
- 44 Urnov, F.D., Reik, A., Vierstra, J., Chang, K.-H., Zhou, Y., Mich, A. et al. (2015) Clinical-scale genome editing of the human BCL11A erythroid enhancer for treatment of the hemoglobinopathies. *Blood* **126**, 204
- 45 Maeda, T., Ito, K., Merghoub, T., Poliseno, L., Hobbs, R.M., Wang, G. et al. (2009) LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. *Dev. Cell* **17**, 527–540 <https://doi.org/10.1016/j.devcel.2009.09.005>
- 46 Lunardi, A., Guarnerio, J., Wang, G., Maeda, T. and Pandolfi, P.P. (2013) Role of LRF/Pokemon in lineage fate decisions. *Blood* **121**, 2845–2853 <https://doi.org/10.1182/blood-2012-11-292037>
- 47 Sankaran, V.G., Greisman, H.A., Weatherall, D.J., Groudine, M. and Premawardhena, A. (2011) A functional element necessary for fetal hemoglobin silencing. *N. Engl. J. Med.* **365**, 807–814 <https://doi.org/10.1056/NEJMoa1103070>

- 48 Bauer, D.E., Kamran, S.C. and Orkin, S.H. (2012) Reawakening fetal hemoglobin: prospects for new therapies for the β -globin disorders. *Blood* **120**, 2945–2953 <https://doi.org/10.1182/blood-2012-06-292078>
- 49 Traxler, E.A., Yao, Y., Wang, Y.-D., Woodard, K.J., Kurita, R., Nakamura, Y. et al. (2016) A genome-editing strategy to treat β -hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. *Nat. Med.* **22**, 987–990 <https://doi.org/10.1038/nm.4170>
- 50 Liu, N., Hargreaves, V.V., Zhu, Q., Kurland, J.V., Hong, J., Kim, W. et al. (2018) Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch. *Cell* **173**, 430–442.e17 <https://doi.org/10.1016/j.cell.2018.03.016>
- 51 Martyn, G.E., Wienert, B., Yang, L., Shah, M., Norton, L.J., Burdach, J. et al. (2018) Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. *Nat. Genet.* **50**, 498–503 <https://doi.org/10.1038/s41588-018-0085-0>
- 52 Ye, L., Wang, J., Tan, Y., Beyer, A.I., Xie, F., Muench, M.O. et al. (2016) Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: an approach for treating sickle cell disease and β -thalassemia. *Proc. Natl Acad. Sci. U.S.A.* **113**, 10661–10665 <https://doi.org/10.1073/pnas.1612075113>
- 53 Antoniani, C., Meneghini, V., Lattanzi, A., Felix, T., Romano, O., Magrin, E. et al. (2018) Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β -globin locus. *Blood* **131**, 1960–1973 <https://doi.org/10.1182/blood-2017-10-811505>
- 54 Traxler, E., Yao, Y., Li, C., Grevet, J., Huang, P., Wright, S. et al. (2015) Genome editing recreates hereditary persistence of fetal hemoglobin in primary human erythroblasts. *Blood* **126**, 640 <https://doi.org/10.1182/blood-2015-03-635532>
- 55 Chung, J.E., Magis, W., Vu, J., Heo, S.-J., Wartiovaara, K., Walters, M.C. et al. (2015) CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells. *PLoS ONE* **14**, e0208237 <https://doi.org/10.1371/journal.pone.0208237>
- 56 Deng, W., Lee, J., Wang, H., Miller, J., Reik, A., Gregory, P.D. et al. (2012) Controlling long-range genomic interactions at a native locus by targeted tethering of a looping factor. *Cell* **149**, 1233–1244 <https://doi.org/10.1016/j.cell.2012.03.051>
- 57 Deng, W., Rupon, J.W., Krivega, I., Breda, L., Motta, I., Jahn, K.S. et al. (2014) Reactivation of developmentally silenced globin genes by forced chromatin looping. *Cell* **158**, 849–860 <https://doi.org/10.1016/j.cell.2014.05.050>
- 58 Mendenhall, E.M., Williamson, K.E., Reyon, D., Zou, J.Y., Ram, O., Joung, J.K. et al. (2013) Locus-specific editing of histone modifications at endogenous enhancers. *Nat. Biotechnol.* **31**, 1133–1136 <https://doi.org/10.1038/nbt.2701>
- 59 Xu, J., Bauer, D.E., Kerenyi, M.A., Vo, T.D., Hou, S., Hsu, Y.-J. et al. (2013) Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. *Proc. Natl Acad. Sci. U.S.A.* **110**, 6518–6523 <https://doi.org/10.1073/pnas.1303976110>
- 60 Kransdorf, E.P., Wang, S.Z., Zhu, S.Z., Langston, T.B., Rupon, J.W. and Ginder, G.D. (2006) MBD2 is a critical component of a methyl cytosine-binding protein complex isolated from primary erythroid cells. *Blood* **108**, 2836–2845 <https://doi.org/10.1182/blood-2006-04-016394>
- 61 Gnanaprasagam, M.N., Scarsdale, J.N., Amaya, M.L., Webb, H.D., Desai, M.A., Walavalkar, N.M. et al. (2011) P66 α -MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2–NuRD complex. *Proc. Natl Acad. Sci. U.S.A.* **108**, 7487–7492 <https://doi.org/10.1073/pnas.1015341108>
- 62 Rees, H.A. and Liu, D.R. (2018) Base editing: precision chemistry on the genome and transcriptome of living cells. *Nat. Rev. Genet.* **19**, 770–788 <https://doi.org/10.1038/s41576-018-0059-1>
- 63 Gaudelli, N.M., Komor, A.C., Rees, H.A., Packer, M.S., Badran, A.H., Bryson, D.I. et al. (2017) Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature* **551**, 464–471 <https://doi.org/10.1038/nature24644>
- 64 Gehrke, J.M., Cervantes, O., Clement, M.K., Wu, Y., Zeng, J., Bauer, D.E. et al. (2018) An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. *Nat. Biotechnol.* **36**, 977–982 <https://doi.org/10.1038/nbt.4199>
- 65 Liang, P., Ding, C., Sun, H., Xie, X., Xu, Y., Zhang, X. et al. (2017) Correction of β -thalassaemia mutant by base editor in human embryos. *Protein Cell* **8**, 811–822 <https://doi.org/10.1007/s13238-017-0475-6>
- 66 Kim, S., Kim, D., Cho, S.W., Kim, J. and Kim, J.-S. (2014) Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome Res.* **24**, 1012–1019 <https://doi.org/10.1101/gr.171322.113>
- 67 Sun, L., Wu, J., Du, F., Chen, X. and Chen, Z.J. (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type-I interferon pathway. *Science* **339**, 786–791 <https://doi.org/10.1126/science.1232458>
- 68 Hendel, A., Bak, R.O., Clark, J.T., Kennedy, A.B., Ryan, D.E., Roy, S. et al. (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. *Nat. Biotechnol.* **33**, 985–989 <https://doi.org/10.1038/nbt.3290>
- 69 Vakulskas, C.A., Dever, D.P., Rettig, G.R., Turck, R., Jacobi, A.M., Collingwood, M.A. et al. (2018) A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. *Nat. Med.* **24**, 1216–1224 <https://doi.org/10.1038/s41591-018-0137-0>
- 70 Hoban, M.D., Lumaquin, D., Kuo, C.Y., Romero, Z., Long, J., Ho, M. et al. (2016) CRISPR/Cas9-mediated correction of the sickle mutation in human CD34⁺ cells. *Mol. Ther.* **24**, 1561–1569 <https://doi.org/10.1038/mt.2016.148>
- 71 Kuo, C.Y., Long, J.D., Campo-Fernandez, B., de Oliveira, S., Cooper, A.R., Romero, Z. et al. (2018) Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome. *Cell Rep.* **23**, 2606–2616 <https://doi.org/10.1016/j.celrep.2018.04.103>
- 72 Charlesworth, C.T., Camarena, J., Cromer, M.K., Vaidyanathan, S., Bak, R.O., Carte, J.M. et al. (2018) Priming human repopulating hematopoietic stem and progenitor cells for Cas9/sgRNA gene targeting. *Mol. Ther. Nucleic Acids* **12**, 89–104 <https://doi.org/10.1016/j.omtn.2018.04.017>
- 73 Dever, D.P., Bak, R.O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C.E. et al. (2016) CRISPR/Cas9 β -globin gene targeting in human hematopoietic stem cells. *Nature* **539**, 384–389 <https://doi.org/10.1038/nature20134>
- 74 Bak, R.O. and Porteus, M.H. (2017) CRISPR-mediated integration of large gene cassettes using AAV donor vectors. *Cell Rep.* **20**, 750–756 <https://doi.org/10.1016/j.celrep.2017.06.064>
- 75 Finn, J.D., Smith, A.R., Patel, M.C., Shaw, L., Youniss, M.R., van Heteren, J. et al. (2018) A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. *Cell Rep.* **22**, 2227–2235 <https://doi.org/10.1016/j.celrep.2018.02.014>
- 76 Lee, K., Conboy, M., Park, H.M., Jiang, F., Kim, H.J., Dewitt, M.A. et al. (2017) Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. *Nat. Biomed. Eng.* **1**, 889–901 <https://doi.org/10.1038/s41551-017-0137-2>
- 77 Li, J., Summerlin, M., Nitiss, K.C., Nitiss, J.L. and Hanakahi, L.A. (2017) TDP1 is required for efficient non-homologous end joining in human cells. *DNA Repair* **60**, 40–49 <https://doi.org/10.1016/j.dnarep.2017.10.003>
- 78 Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y. et al. (2015) Small molecules enhance CRISPR genome editing in pluripotent stem cells. *Cell Stem Cell* **16**, 142–147 <https://doi.org/10.1016/j.stem.2015.01.003>

- 79 Boitano, A.E., Wang, J., Romeo, R., Bouchez, L.C., Parker, A.E., Sutton, S.E. et al. (2010) Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. *Science* **329**, 1345–1348 <https://doi.org/10.1126/science.1191536>
- 80 North, T.E., Goessling, W., Walkley, C.R., Lengerke, C., Kopani, K.R., Lord, A.M. et al. (2007) Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. *Nature* **447**, 1007–1011 <https://doi.org/10.1038/nature05883>
- 81 Li, G., Zhang, X., Zhong, C., Mo, J., Quan, R., Yang, J. et al. (2017) Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells. *Sci. Rep.* **7**, 8943 <https://doi.org/10.1038/s41598-017-09306-x>
- 82 Song, J., Yang, D., Xu, J., Zhu, T., Chen, Y.E. and Zhang, J. (2016) RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. *Nat. Commun.* **7**, 10548 <https://doi.org/10.1038/ncomms10548>
- 83 Orthwein, A., Noordermeer, S.M., Wilson, M.D., Landry, S., Enchev, R.I., Sherker, A. et al. (2015) A mechanism for the suppression of homologous recombination in G1 cells. *Nature* **528**, 422–426 <https://doi.org/10.1038/nature16142>
- 84 Zonari, E., Desantis, G., Petrillo, C., Boccalatte, F.E., Lidonni, M.R., Kajaste-Rudnitski, A. et al. (2017) Efficient ex vivo engineering and expansion of highly purified human hematopoietic stem and progenitor cell populations for gene therapy. *Stem Cell Rep.* **8**, 977–990 <https://doi.org/10.1016/j.stemcr.2017.02.010>
- 85 Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K. et al. (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nat. Biotechnol.* **31**, 822–826 <https://doi.org/10.1038/nbt.2623>
- 86 Gabriel, R., von Kalle, C. and Schmidt, M. (2015) Mapping the precision of genome editing. *Nat. Biotechnol.* **33**, 150–152 <https://doi.org/10.1038/nbt.3142>
- 87 Frock, R.L., Hu, J., Meyers, R.M., Ho, Y.-J., Kii, E. and Alt, F.W. (2015) Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. *Nat. Biotechnol.* **33**, 179–186 <https://doi.org/10.1038/nbt.3101>
- 88 Tsai, S.Q., Zheng, Z., Nguyen, N.T., Liebers, M., Topkar, V.V., Thapar, V. et al. (2015) GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat. Biotechnol.* **33**, 187–197 <https://doi.org/10.1038/nbt.3117>
- 89 Kim, D., Bae, S., Park, J., Kim, E., Kim, S., Yu, H.R. et al. (2015) Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. *Nat. Methods* **12**, 237–243 <https://doi.org/10.1038/nmeth.3284>
- 90 Tsai, S.Q., Wyvekens, N., Khayter, C., Foden, J.A., Thapar, V., Reyon, D. et al. (2014) Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. *Nat. Biotechnol.* **32**, 569–576 <https://doi.org/10.1038/nbt.2908>
- 91 Mali, P., Aach, J., Stranges, P.B., Esvelt, K.M., Moosburner, M., Kosuri, S. et al. (2013) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. *Nat. Biotechnol.* **31**, 833–838 <https://doi.org/10.1038/nbt.2675>
- 92 Kleinstiver, B.P., Pattanayak, V., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z. et al. (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* **529**, 490–495 <https://doi.org/10.1038/nature16526>